Cargando…
The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687623/ https://www.ncbi.nlm.nih.gov/pubmed/26719716 http://dx.doi.org/10.2147/CEOR.S87261 |
_version_ | 1782406648281694208 |
---|---|
author | Walker, David R Juday, Timothy R Manthena, Shivaji R Jing, Yonghua Sood, Vipan |
author_facet | Walker, David R Juday, Timothy R Manthena, Shivaji R Jing, Yonghua Sood, Vipan |
author_sort | Walker, David R |
collection | PubMed |
description | BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this study is to examine the impact of pill count on real-world adherence rates in patients treated with SOF + SIM with and without RBV. METHODS: This retrospective study assessed composite adherence to SOF and SIM over 12 weeks of treatment for two cohorts of hepatitis C patients: one initiating SOF + SIM therapy, and the other initiating SOF + SIM + RBV therapy. Analyses were conducted using MarketScan(®) and Optum US commercial pharmacy claims and enrollment data. Adherence was adjusted by treatment regimen, age, sex, co-pay, presence/absence of cirrhosis, treatment history, and Charlson Comorbidity Index. RESULTS: There was a significant difference in composite unadjusted and adjusted adherence rates for SOF and SIM for the SOF + SIM vs SOF + SIM + RBV cohorts based on MarketScan data (unadjusted, 92.6% and 89.7%, respectively; P=0.0423; adjusted, 92.2% and 88.7%, respectively; P=0.0176), but not based on Optum data (unadjusted, 94.8% and 95.6%, respectively; P=0.5618; adjusted, 94.8% and 95.1%, respectively; P=0.8589). In the MarketScan and Optum databases, there were no statistical differences in unadjusted and adjusted adherence rates for SOF. Unadjusted and adjusted adherence rates for SIM were mixed, as they were for composite adherence. CONCLUSION: The impact of the addition of RBV to SOF + SIM therapy was mixed. The impact of RBV on SOF adherence was not significant in either database. |
format | Online Article Text |
id | pubmed-4687623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46876232015-12-30 The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir Walker, David R Juday, Timothy R Manthena, Shivaji R Jing, Yonghua Sood, Vipan Clinicoecon Outcomes Res Original Research BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this study is to examine the impact of pill count on real-world adherence rates in patients treated with SOF + SIM with and without RBV. METHODS: This retrospective study assessed composite adherence to SOF and SIM over 12 weeks of treatment for two cohorts of hepatitis C patients: one initiating SOF + SIM therapy, and the other initiating SOF + SIM + RBV therapy. Analyses were conducted using MarketScan(®) and Optum US commercial pharmacy claims and enrollment data. Adherence was adjusted by treatment regimen, age, sex, co-pay, presence/absence of cirrhosis, treatment history, and Charlson Comorbidity Index. RESULTS: There was a significant difference in composite unadjusted and adjusted adherence rates for SOF and SIM for the SOF + SIM vs SOF + SIM + RBV cohorts based on MarketScan data (unadjusted, 92.6% and 89.7%, respectively; P=0.0423; adjusted, 92.2% and 88.7%, respectively; P=0.0176), but not based on Optum data (unadjusted, 94.8% and 95.6%, respectively; P=0.5618; adjusted, 94.8% and 95.1%, respectively; P=0.8589). In the MarketScan and Optum databases, there were no statistical differences in unadjusted and adjusted adherence rates for SOF. Unadjusted and adjusted adherence rates for SIM were mixed, as they were for composite adherence. CONCLUSION: The impact of the addition of RBV to SOF + SIM therapy was mixed. The impact of RBV on SOF adherence was not significant in either database. Dove Medical Press 2015-12-17 /pmc/articles/PMC4687623/ /pubmed/26719716 http://dx.doi.org/10.2147/CEOR.S87261 Text en © 2015 Walker et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Walker, David R Juday, Timothy R Manthena, Shivaji R Jing, Yonghua Sood, Vipan The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
title | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
title_full | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
title_fullStr | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
title_full_unstemmed | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
title_short | The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir |
title_sort | impact of ribavirin on real-world adherence rates in hepatitis c patients treated with sofosbuvir plus simeprevir |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687623/ https://www.ncbi.nlm.nih.gov/pubmed/26719716 http://dx.doi.org/10.2147/CEOR.S87261 |
work_keys_str_mv | AT walkerdavidr theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT judaytimothyr theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT manthenashivajir theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT jingyonghua theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT soodvipan theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT walkerdavidr impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT judaytimothyr impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT manthenashivajir impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT jingyonghua impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir AT soodvipan impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir |